Skip to main content
Premium Trial:

Request an Annual Quote

Small Bits of Cancer

Premium

Researchers at the Massachusetts General Hospital in Boston have signed a five-year, $30 million with Johnson and Johnson to bring to market a test that can detect small amounts of cancer cells in blood, reports The Boston Globe's Carolyn Johnson. The researchers have already developed a prototype of the microchip, and the partnership is aimed at refining the test and commercializing it, Johnson adds. The test, which is non-invasive, could be used to track the progress of a person's disease by recording the levels of cancer cells found in the blood of any given patient. It could also allow doctors to test the cells themselves for specific mutations in order to come up with the best treatment options, Johnson says. Veridex, the Johnson and Johnson company involved in the deal, will help the researchers to clear regulatory hurdles and set up clinical trials to validate new tests.

The next step, says In the Pipeline's Derek Lowe, is to develop better therapies, so that when patients find out their current regimen may not be working, there are other options waiting. "If these circulating-cell assays help us sort things out faster in the clinic, maybe we'll be able to make better use of our time and money to that end," Lowe says.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.